RDG Stock Overview
Read-Gene S.A. engages in the detection, prevention, and treatment of various types of malignant tumors.
Price History & Performance
|Historical stock prices|
|Current Share Price||zł2.51|
|52 Week High||zł3.30|
|52 Week Low||zł2.20|
|1 Month Change||-6.69%|
|3 Month Change||-10.99%|
|1 Year Change||-15.20%|
|3 Year Change||185.23%|
|5 Year Change||36.41%|
|Change since IPO||-7.04%|
Recent News & Updates
|RDG||PL Biotechs||PL Market|
Return vs Industry: RDG exceeded the Polish Biotechs industry which returned -40% over the past year.
Return vs Market: RDG matched the Polish Market which returned -15.6% over the past year.
|RDG Average Weekly Movement||10.4%|
|Biotechs Industry Average Movement||7.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in PL Market||13.4%|
|10% least volatile stocks in PL Market||4.5%|
Stable Share Price: RDG is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: RDG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
Read-Gene S.A. engages in the detection, prevention, and treatment of various types of malignant tumors. Its activities include chemoprevention, clinical trials, and genetic tests. Chemoprevention is the use of natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer.
Read-Gene Fundamentals Summary
|RDG fundamental statistics|
Is RDG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RDG income statement (TTM)|
|Cost of Revenue||zł803.81k|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
May 31, 2022
|Earnings per share (EPS)||-0.00002|
|Net Profit Margin||-0.004%|
How did RDG perform over the long term?See historical performance and comparison
Is Read-Gene undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: RDG (PLN2.51) is trading above our estimate of fair value (PLN0.23)
Significantly Below Fair Value: RDG is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RDG is unprofitable, so we can't compare its PE Ratio to the Polish Biotechs industry average.
PE vs Market: RDG is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RDG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RDG is overvalued based on its PB Ratio (8.1x) compared to the PL Biotechs industry average (4.5x).
How is Read-Gene forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Read-Gene has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Read-Gene performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RDG is currently unprofitable.
Growing Profit Margin: RDG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RDG is unprofitable, but has reduced losses over the past 5 years at a rate of 48.2% per year.
Accelerating Growth: Unable to compare RDG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: RDG has a negative Return on Equity (-0.007%), as it is currently unprofitable.
How is Read-Gene's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: RDG's short term assets (PLN8.4M) exceed its short term liabilities (PLN422.7K).
Long Term Liabilities: RDG's short term assets (PLN8.4M) do not cover its long term liabilities (PLN12.1M).
Debt to Equity History and Analysis
Debt Level: RDG is debt free.
Reducing Debt: RDG had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable RDG has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: RDG is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 9.6% per year.
What is Read-Gene current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RDG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RDG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RDG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RDG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as RDG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Prof, Dr. HAB. N. MED. Jan Lubinski serves as President of the Management Board at Read-Gene SA. Prof. Lubinski served as the Chief Executive Officer of Read-Gene SA.Prof. Lubinski is one of the most famo...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Read-Gene S.A.'s employee growth, exchange listings and data sources
- Name: Read-Gene S.A.
- Ticker: RDG
- Exchange: WSE
- Founded: 2005
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł29.593m
- Shares outstanding: 11.79m
- Website: https://www.read-gene.com
Number of Employees
- Read-Gene S.A.
- ul. Alabastrowa 8
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/23 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.